Dermatomyositis

Last updated

Dermatomyositis
Dermatomyositis.jpg
Discrete red areas overlying the knuckles in a person with juvenile dermatomyositis. These are known as Gottron's papules.
Specialty Rheumatology
Symptoms Rash, muscle weakness, weight loss, fever [1]
Complications Calcinosis, lung inflammation, heart disease [1] [2]
Usual onset40s to 50s [3]
Duration Long term [1]
CausesUnknown [1]
Diagnostic method Based on symptoms, blood tests, electromyography, muscle biopsies [3]
Differential diagnosis Polymyositis, inclusion body myositis, scleroderma [3]
TreatmentMedication, physical therapy, exercise, heat therapy, orthotics, assistive devices, rest [1]
Medication Corticosteroids, methotrexate, azathioprine [1]
Frequency~ 1 per 100,000 people per year [3]

Dermatomyositis (DM) is a long-term inflammatory disorder which affects the skin and the muscles. [1] Its symptoms are generally a skin rash and worsening muscle weakness over time. [1] These may occur suddenly or develop over months. [1] Other symptoms may include weight loss, fever, lung inflammation, or light sensitivity. [1] Complications may include calcium deposits in muscles or skin. [1]

Contents

The cause is unknown. [1] Theories include that it is an autoimmune disease or a result of a viral infection. [1] Dermatomyositis may develop as a paraneoplastic syndrome associated with several forms of malignancy. [4] It is a type of inflammatory myopathy. [1] Diagnosis is typically based on some combination of symptoms, blood tests, electromyography, and muscle biopsies. [3]

Eighty percent of adults with adult-onset dermatomyositis have a myositis-specific antibody (MSA). [5]

Sixty percent of children with juvenile dermatomyositis have a myositis-specific antibody (MSA). [6]

Although no cure for the condition is known, treatments generally improve symptoms. [1] Treatments may include medication, physical therapy, exercise, heat therapy, orthotics, and assistive devices, and rest. [1] Medications in the corticosteroids family are typically used with other agents such as methotrexate or azathioprine recommended if steroids are not working well. [1] Intravenous immunoglobulin may also improve outcomes. [1] Most people improve with treatment and in some, the condition resolves completely. [1]

About one per 100,000 people per year are newly affected. [3] The condition usually occurs in those in their 40s and 50s with women being affected more often than men. [3] People of any age, however, may be affected. [3] The condition was first described in the 1800s. [7]

Signs and symptoms

The main symptoms include several kinds of skin rash along with muscle weakness in both upper arms or thighs. [2]

Skin

One form the rashes take is called "heliotrope" (a purplish color) or lilac, but may also be red. It can occur around the eyes along with swelling, but also occurs on the upper chest or back what is called the "shawl" (around the neck) or "V-sign" above the breasts and may also occur on the face, upper arms, thighs, or hands. [8] Another form the rash takes is called Gottron's sign, which is red or violet, sometimes scaly, slightly raised papules that erupt on any of the finger joints (the metacarpophalangeal joints or the interphalangeal joints). [8] [9] Gottron's papules may also be found over other bony prominences including the elbows, knees, or feet. All these rashes are made worse by exposure to sunlight, and are often very itchy, painful, and may bleed. [9]

If a person exhibits only skin findings characteristic of DM, without weakness or abnormal muscle enzymes, then he or she may be experiencing amyopathic dermatomyositis (ADM), formerly known as "dermatomyositis sine myositis". [10]

Muscles

People with DM experience progressively worsening muscle weakness in the proximal muscles (for example, the shoulders and thighs). [11] Tasks that use these muscles: standing from sitting, lifting, and climbing stairs, can become increasingly difficult for people with dermatomyositis. [11]

Other

Around 30% of people have swollen, painful joints, but this is generally mild. [12]

In some people, the condition affects the lungs, and they may have a cough or difficulty breathing. If the disease affects the heart, arrhythmias may occur. If it affects the blood vessels in the stomach or intestines, which is more common in juvenile DM, the people might vomit blood, have black tarry bowel movements, or may develop a hole somewhere in their GI tract. [12]

There are further complications possible with dermatomyositis. These complications include difficulty swallowing due to the muscles in the esophagus being affected which can result in malnutrition and can cause the breathing of food or liquids, into the lungs.

Causes

The cause is unknown, but it may result from an initial viral infection or cancer, either of which could raise an autoimmune response. [12]

Between 7 and 30% of dermatomyositis cases arise from cancer, probably as an autoimmune response. [13] The most commonly associated cancers are ovarian cancer, breast cancer, and lung cancer. [13] Between 18 and 25 per cent of people with amyopathic DM also have cancer. [9] Malignancy in association with dermatomyositis is more prevalent after age 60.

Some cases are inherited, and HLA subtypes HLA-DR3, HLA-DR52, and HLA-DR6 seem to create a disposition to autoimmune dermatomyositis. [12]

Diagnosis

Calcification from dermatomyositis Dermatomyocitis.png
Calcification from dermatomyositis
X-Ray of the knee in a person with dermatomyositis. XRaydermatomyositis.jpg
X-Ray of the knee in a person with dermatomyositis.
Micrograph of dermatomyositis, muscle biopsy, H&E stain Dermatomyositis - high mag.jpg
Micrograph of dermatomyositis, muscle biopsy, H&E stain

The diagnosis of dermatomyositis is based on five criteria, which are also used to differentially diagnose with respect to polymyositis: [10]

  1. Muscle weakness in both thighs or both upper arms
  2. Using a blood test, finding higher levels of enzymes found in skeletal muscle, including creatine kinase, aldolase, and glutamate oxaloacetate, pyruvate transaminases and lactate dehydrogenase
  3. Using electromyography (testing of electric signalling in muscles), finding all three of: erratic, repetitive, high-frequency signals; short, low-energy signals between skeletal muscles and motor neurons that have multiple phases; and sharp activity when a needle is inserted into the muscle
  4. Examining a muscle biopsy under a microscope and finding mononuclear white blood cells between the muscle cells, and finding abnormal muscle cell degeneration and regeneration, dying muscle cells, and muscle cells being consumed by other cells (phagocytosis)
  5. Rashes typical of dermatomyositis, which include heliotrope rash, Gottron sign, and Gottron papules

The fifth criterion is what differentiates dermatomyositis from polymyositis; the diagnosis is considered definite for dermatomyositis if three of items 1 through 4 are present in addition to 5, probable with any two in addition to 5, and possible if just one is present in addition to 5. [10]

Dermatomyositis is associated with autoantibodies, especially antinuclear antibodies (ANA). [12] Around 80% of people with DM test positive for ANA and around 30% of people have myositis-specific autoantibodies which include antibodies to aminoacyl-tRNA synthetases (anti-synthetase antibodies), including antibodies against histidine—tRNA ligase (Anti-Jo1); antibodies to signal recognition particle (SRP); and anti-Mi-2 antibodies. [12]

Magnetic resonance imaging may be useful to guide muscle biopsy and to investigate involvement of internal organs; [14] X-ray may be used to investigate joint involvement and calcifications. [15]

A given case of dermatomyositis may be classified as amyopathic dermatomyositis if only skin is affected and no muscle weakness for longer than 6 months is seen according to one 2016 review, [10] or two years according to another. [9]

Classification

Dermatomyositis is a form of systemic connective tissue disorder, a class of diseases that often involves autoimmune dysfunction. [12] [16]

It has also been classified as an idiopathic inflammatory myopathy, along with polymyositis, necrotizing autoimmune myositis, cancer-associated myositis, and sporadic inclusion body myositis. [17]

A form of this disorder that occurs prior to adulthood is known as juvenile dermatomyositis. [18]

Treatment

No cure for dermatomyositis is known, but the symptoms can be treated. Options include medication, physical therapy, exercise, heat therapy (including microwave and ultrasound), orthotics and assistive devices, and rest. The standard treatment for dermatomyositis is a corticosteroid drug, given either in pill form or intravenously. Immunosuppressant drugs, such as azathioprine and methotrexate, may reduce inflammation in people who do not respond well to prednisone. Periodic treatment using intravenous immunoglobulin can also improve recovery. Other immunosuppressive agents used to treat the inflammation associated with dermatomyositis include cyclosporine A, cyclophosphamide, and tacrolimus. [19]

Physical therapy is usually recommended to prevent muscle atrophy and to regain muscle strength and range of motion. Many individuals with dermatomyositis may need a topical ointment, such as topical corticosteroids, for their skin disorder. They should wear high-protection sunscreen and protective clothing. Surgery may be required to remove calcium deposits that cause nerve pain and recurrent infections. [20]

Antimalarial medications, especially hydroxychloroquine and chloroquine, are used to treat the rashes, as is done for similar conditions. [9]

Rituximab is used when people do not respond to other treatments. [21] [22]

As of 2016, treatments for amyopathic dermatomyositis in adults did not have a strong evidence base; published treatments included antimalarial medications, steroids, taken or orally or applied to the skin, calcineurin inhibitors applied to the skin, dapsone, intravenous immunoglobulin, methotrexate, azathioprine, and mycophenolate mofetil. None appears to be very effective; among them, intravenous immunoglobulin has had the best outcomes. [10]

Prognosis

Before the advent of modern treatments such as prednisone, intravenous immunoglobulin, plasmapheresis, chemotherapies, and other drugs, the prognosis was poor. [23]

The cutaneous manifestations of dermatomyositis may or may not improve with therapy in parallel with the improvement of the myositis. In some people, the weakness and rash resolve together. In others, the two are not linked, with one or the other being more challenging to control. Often, cutaneous disease persists after adequate control of the muscle disease. [24] [25]

The risk of death from the condition is much higher if the heart or lungs are affected. [17] [20]

Epidemiology

Incidence of DM peaks at ages 40–50, but the disease can affect people of all ages. [26] [3] It tends to affect more women than men. [3] The prevalence of DM ranges from one to 22 per 100,000 people. [27] [28] [29]

History

The diagnostic criteria were proposed in 1975 and became widely adopted. [9] [30] Amyopathic DM, also called DM sine myositis, was named in 2002. [9]

People who were affected with dermatomyositis

Research

As of 2016, research was ongoing into causes for DM, as well as biomarkers; [36] clinical trials were ongoing for use of the following drugs in DM: ajulemic acid (Phase II), adrenocorticotropic hormone gel (Phase IV, open label), IMO-8400, an antagonist of Toll-like receptor 7,8 and 9 (Ph II), abatacept (Phase IV, open label), and sodium thiosulfate (Phase II). [9]

Related Research Articles

Inclusion body myositis (IBM) is the most common inflammatory muscle disease in older adults. The disease is characterized by slowly progressive weakness and wasting of both proximal muscles and distal muscles, most apparent in the finger flexors and knee extensors. IBM is often confused with an entirely different class of diseases, called hereditary inclusion body myopathies (hIBM). The "M" in hIBM is an abbreviation for "myopathy" while the "M" in IBM is for "myositis". In IBM, two processes appear to occur in the muscles in parallel, one autoimmune and the other degenerative. Inflammation is evident from the invasion of muscle fibers by immune cells. Degeneration is characterized by the appearance of holes, deposits of abnormal proteins, and filamentous inclusions in the muscle fibers. sIBM is a rare disease, with a prevalence ranging from 1 to 71 individuals per million.

<span class="mw-page-title-main">Lambert–Eaton myasthenic syndrome</span> Medical condition

Lambert–Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder characterized by muscle weakness of the limbs. It is also known as myasthenic syndrome, Eaton–Lambert syndrome, and when related to cancer, carcinomatous myopathy.

<span class="mw-page-title-main">Myasthenia gravis</span> Autoimmune disease resulting in skeletal muscle weakness

Myasthenia gravis (MG) is a long-term neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, and difficulties in talking and walking. Onset can be sudden. Those affected often have a large thymus or develop a thymoma.

<span class="mw-page-title-main">Myalgia</span> Painful sensations in muscle tissue

Myalgia or muscle pain is a painful sensation evolving from muscle tissue. It is a symptom of many diseases. The most common cause of acute myalgia is the overuse of a muscle or group of muscles; another likely cause is viral infection, especially when there has been no injury.

<span class="mw-page-title-main">Juvenile dermatomyositis</span> Medical condition

Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune dysfunction resulting in muscle weakness among other complications. It manifests itself in children; it is the pediatric counterpart of dermatomyositis. In JDM, the body's immune system attacks blood vessels throughout the body, causing inflammation called vasculitis. In the United States, the incidence rate of JDMS is approximately 2-3 cases per million children per year. The UK incidence is believed to be between 2-3 per million children per year, with some difference between ethnic groups. The sex ratio is approximately 2:1. Other Idiopathic inflammatory myopathies include; juvenile polymyositis (PM), which is rare and not as common in children as in adults.

In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly. Myopathy means muscle disease. This meaning implies that the primary defect is within the muscle, as opposed to the nerves or elsewhere.

<span class="mw-page-title-main">Polymyositis</span> Medical condition

Polymyositis (PM) is a type of chronic inflammation of the muscles related to dermatomyositis and inclusion body myositis. Its name means 'inflammation of many muscles'. The inflammation of polymyositis is mainly found in the endomysial layer of skeletal muscle, whereas dermatomyositis is characterized primarily by inflammation of the perimysial layer of skeletal muscles.

<span class="mw-page-title-main">Myositis</span> Medical condition

Myositis is a rarely-encountered medical condition characterized by inflammation affecting the muscles. The manifestations of this condition may include skin issues, muscle weakness, and the potential involvement of other organs. Additionally, systemic symptoms like weight loss, fatigue, and low-grade fever can manifest in individuals with myositis.

<span class="mw-page-title-main">Masticatory muscle myositis</span>

Masticatory muscle myositis (MMM) is an inflammatory disease in dogs affecting the muscles of mastication (chewing). It is also known as atrophic myositis or eosinophilic myositis. MMM is the most common inflammatory myopathy in dogs. The disease mainly affects large breed dogs. German Shepherd Dogs and Cavalier King Charles Spaniels may be predisposed. There is a similar disease of the eye muscles found in Golden Retrievers. Symptoms of acute MMM include swelling of the jaw muscles, drooling, and pain on opening the mouth. Ophthalmic signs may include third eyelid protrusion, red eyes, and exophthalmos. In chronic MMM there is atrophy of the jaw muscles, and scarring of the masticatory muscles due to fibrosis may result in inability to open the mouth (trismus). The affected muscles include the temporalis, masseter, and pterygoid muscles. The disease is usually bilateral.

<span class="mw-page-title-main">Chronic inflammatory demyelinating polyneuropathy</span> Medical condition

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating polyradiculoneuropathy. CIDP is closely related to Guillain–Barré syndrome and it is considered the chronic counterpart of that acute disease. Its symptoms are also similar to progressive inflammatory neuropathy. It is one of several types of neuropathy.

Mixed connective tissue disease, commonly abbreviated as MCTD, is an autoimmune disease characterized by the presence of elevated blood levels of a specific autoantibody, now called anti-U1 ribonucleoprotein (RNP), together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.

Gottron's sign is a pathognomonic cutaneous manifestation associated with dermatomyositis (DM), which is an inflammatory disorder affecting the skin and muscles. The primary lesion of dermatomyositis appears as a violaceous, macular erythema with a symmetric distribution, which may progress and become poikilodermatous and indurated.

Scleromyositis, is an autoimmune disease. People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome. Although it is a rare disease, it is one of the more common overlap syndromes seen in scleroderma patients, together with MCTD and Antisynthetase syndrome. Autoantibodies often found in these patients are the anti-PM/Scl (anti-exosome) antibodies.

<span class="mw-page-title-main">Autoimmune disease</span> Disorders of adaptive immune system

An autoimmune disease is a condition that results from an anomalous response of the adaptive immune system, wherein it mistakenly targets and attacks healthy, functioning parts of the body as if they were foreign organisms. It is estimated that there are more than 80 recognized autoimmune diseases, with recent scientific evidence suggesting the existence of potentially more than 100 distinct conditions. Nearly any body part can be involved.

<span class="mw-page-title-main">Inflammatory myopathy</span> Medical condition

Inflammatory myopathy, also known as idiopathic inflammatory myopathy (IIM), is disease featuring muscle weakness, inflammation of muscles (myositis), and in some types, muscle pain. The cause of much inflammatory myopathy is unknown (idiopathic), and such cases are classified according to their symptoms and signs, electromyography, MRI, and laboratory findings. It can also be associated with underlying cancer. The main classes of idiopathic inflammatory myopathy are polymyositis (PM), dermatomyositis (DM), inclusion-body myositis (IBM), immune-mediated necrotising myopathy (IMNM), and focal autoimmune myositis.

Self-healing juvenile cutaneous mucinosis is a skin condition caused by fibroblasts producing abnormally large amounts of mucopolysaccharides, and is characterized by the sudden onset of skin lesions and polyarthritis.

Although they vary in particulars, polymyositis, dermatomyositis and inclusion body myositis are idiopathic inflammatory myopathies (IIM) primarily characterized by chronic inflammation of human skeletal muscle tissue that ultimately causes the necrosis of muscle cells. This degeneration leads to muscle tissue wasting, weakness and fatigue among other serious effects. Until recently, exercise has been avoided as a type of therapy, and even forbidden due to the risk of triggering or amplifying inflammation. However, several studies have been conducted to test this assumption and have shown that aerobic exercise as well as resistance training can maintain and even improve quality of life for IIM-affected individuals without increased inflammatory response.

<span class="mw-page-title-main">Antisynthetase syndrome</span> Medical condition

Antisynthetase syndrome (ASS) is a multisystematic autoimmune disease associated with inflammatory myositis, interstitial lung disease, and antibodies directed against various synthetases of aminoacyl-transfer RNA. Other common symptoms include mechanic's hands, Raynaud's phenomenon, arthritis, and fever.

Immunoglobulin therapy is the use of a mixture of antibodies to treat several health conditions. These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a more specific immunoglobulin is not available. Depending on the formulation it can be given by injection into muscle, a vein, or under the skin. The effects last a few weeks.

Statin-associated autoimmune myopathy (SAAM), also known as anti-HMGCR myopathy, is a very rare form of muscle damage caused by the immune system in people who take statin medications. However, there are cases of SAAM in patients who have not taken statin medication, and this can be explained by the exposure to natural sources of statin such as red yeast rice, which is statin rich. This theory is supported by the higher prevalence of statin-naive SAAM patients in Asian cohorts, who have statin-rich diets.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 "Dermatomyositis". GARD. 2017. Archived from the original on 5 July 2017. Retrieved 13 July 2017.
  2. 1 2 Callen JP, Wortmann RL (September 2006). "Dermatomyositis". Clinics in Dermatology. 24 (5): 363–373. doi:10.1016/j.clindermatol.2006.07.001. PMID   16966018.
  3. 1 2 3 4 5 6 7 8 9 10 "Dermatomyositis". NORD (National Organization for Rare Disorders). 2015. Archived from the original on 19 February 2017. Retrieved 13 July 2017.
  4. ↑ Tudorancea AD, Ciurea PL, Vreju AF, Turcu-Stiolica A, Gofita CE, Criveanu C, Musetescu AE, Dinescu SC (July 2021). "A Study on Dermatomyositis and the Relation to Malignancy". Current Health Sciences Journal. 47 (3): 377–382. doi:10.12865/CHSJ.47.03.07. PMC   8679146 . PMID   35003769.
  5. ↑ Tansley SL, McHugh NJ, Wedderburn LR (2013). "Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?". Arthritis Research & Therapy. 15 (2): 211. doi: 10.1186/ar4198 . PMC   3672700 . PMID   23566358. Myositis-specific autoantibodies (MSAs) can now be identified in 80% of adults.
  6. ↑ Papadopoulou C, Chew C, Wilkinson MG, McCann L, Wedderburn LR (June 2023). "Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care". Nature Reviews Rheumatology. 19 (6): 343–362. doi:10.1038/s41584-023-00967-9. PMC   10184643 . PMID   37188756. Approximately 60% of patients with JDM are positive for a myositis-specific antibody (MSA).
  7. ↑ "History of Dermatomyositis". Dermatomyositis. 2009. pp. 5–8. doi:10.1007/978-3-540-79313-7_2. ISBN   978-3-540-79312-0.
  8. 1 2 Callen JP (June 2010). "Cutaneous Manifestations of Dermatomyositis and Their Management". Current Rheumatology Reports. 12 (3): 192–197. doi:10.1007/s11926-010-0100-7. PMID   20425525. S2CID   29083422.
  9. 1 2 3 4 5 6 7 8 Kuhn A, Landmann A, Bonsmann G (October 2016). "The skin in autoimmune diseases-Unmet needs". Autoimmunity Reviews. 15 (10): 948–54. doi:10.1016/j.autrev.2016.07.013. PMID   27481041.
  10. 1 2 3 4 5 Callander J, Robson Y, Ingram J, Piguet V (11 May 2016). "Treatment of clinically amyopathic dermatomyositis in adults: a systematic review". The British Journal of Dermatology. 179 (6): 1248–1255. doi:10.1111/bjd.14726. PMID   27167896. S2CID   45638288.
  11. 1 2 Dalakas MC (30 April 2015). "Inflammatory Muscle Diseases". New England Journal of Medicine. 372 (18): 1734–1747. doi:10.1056/NEJMra1402225. PMID   25923553. S2CID   37761391.
  12. 1 2 3 4 5 6 7 Hajj-ali RA (June 2013). "Polymyositis and Dermatomyositis – Musculoskeletal and Connective Tissue Disorders". Merck Manuals Professional Edition. Archived from the original on 12 October 2015.
  13. 1 2 Di Rollo D, Abeni D, Tracanna M, Capo A, Amerio P (October 2014). "Cancer risk in dermatomyositis: a systematic review of the literature". Giornale Italiano di Dermatologia e Venereologia. 149 (5): 525–537. PMID   24975953.
  14. ↑ Simon JP, Marie I, Jouen F, Boyer O, Martinet J (14 June 2016). "Autoimmune Myopathies: Where Do We Stand?". Frontiers in Immunology. 7: 234. doi: 10.3389/fimmu.2016.00234 . PMC   4905946 . PMID   27379096.
  15. ↑ Ramos-E-Silva M, Lima Pinto AP, Pirmez R, Cuzzi T, Carneiro S (1 October 2016). "Dermatomyositis-Part 2: Diagnosis, Association With Malignancy, and Treatment". Skinmed. 14 (5): 354–358. PMID   27871347.
  16. ↑ "ICD-10 Systemic connective tissue disorders (M30-M36)". WHO. Archived from the original on 8 February 2017. Retrieved 9 December 2016.
  17. 1 2 Danieli MG, Gelardi C, Guerra F, Cardinaletti P, Pedini V, Gabrielli A (May 2016). "Cardiac involvement in polymyositis and dermatomyositis". Autoimmunity Reviews. 15 (5): 462–5. doi:10.1016/j.autrev.2016.01.015. PMID   26826433.
  18. ↑ Feldman BM, Rider LG, Reed AM, Pachman LM (June 2008). "Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood". Lancet. 371 (9631): 2201–2212. doi:10.1016/S0140-6736(08)60955-1. PMID   18586175. S2CID   205951454.
  19. ↑ "Dermatomyositis (DM)". The Lecturio Medical Concept Library. Retrieved 11 July 2021.
  20. 1 2 "Dermatomyositis Information". National Institute of Neurological Disorders and Stroke. 27 July 2015. Archived from the original on 2 December 2016.
  21. ↑ Malik A, Hayat G, Kalia JS, Guzman MA (20 May 2016). "Idiopathic Inflammatory Myopathies: Clinical Approach and Management". Frontiers in Neurology. 7: 64. doi: 10.3389/fneur.2016.00064 . PMC   4873503 . PMID   27242652.
  22. ↑ Wright NA, Vleugels RA, Callen JP (January 2016). "Cutaneous dermatomyositis in the era of biologicals". Seminars in Immunopathology. 38 (1): 113–21. doi:10.1007/s00281-015-0543-z. PMID   26563285. S2CID   7104535.
  23. ↑ Page 285 in: Thomson and Cotton Lecture Notes in Pathology, Blackwell Scientific. Third Edition
  24. ↑ "Dermatomyositis". Genetic and Rare Diseases Information Center (GARD). Retrieved 11 July 2021.
  25. ↑ "Dermatomyositis". Johns Hopkins Medicine. 19 November 2019. Retrieved 11 July 2021.
  26. ↑ Tymms KE, Webb J (December 1985). "Dermatopolymyositis and other connective tissue diseases: a review of 105 cases". The Journal of Rheumatology. 12 (6): 1140–1148. PMID   4093921.
  27. ↑ Cooper GS, Stroehla BC (May 2003). "The epidemiology of autoimmune diseases". Autoimmunity Reviews. 2 (3): 119–125. doi:10.1016/s1568-9972(03)00006-5. PMID   12848952.
  28. ↑ Bernatsky S, Joseph L, Pineau CA, Belisle P, Boivin JF, Banerjee D, Clarke AE (July 2009). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. PMID   18713785. S2CID   21500536.
  29. ↑ Bendewald MJ, Wetter DA, Li X, Davis MD (2010). "Incidence of Dermatomyositis and Clinically Amyopathic Dermatomyositis: A Population-Based Study in Olmsted County, Minnesota". Archives of Dermatology. 146 (1): 26–30. doi:10.1001/archdermatol.2009.328. PMC   2886726 . PMID   20083689.
  30. ↑ Bohan A, Peter JB (13 February 1975). "Polymyositis and Dermatomyositis: (First of Two Parts)". New England Journal of Medicine. 292 (7): 344–347. doi:10.1056/nejm197502132920706. PMID   1090839. and Bohan A, Peter JB (20 February 1975). "Polymyositis and Dermatomyositis: (Second of Two Parts)". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/nejm197502202920807. PMID   1089199.
  31. ↑ "Greek Reporter: 'Maria Callas did not kill herself from grief for Onassis, a rare disease cost her career and life'". GR Reporter. 28 December 2010. Archived from the original on 4 January 2015. Retrieved 1 January 2015.
  32. ↑ "Laurence Olivier Dies: 'The Rest Is Silence'". People Magazine. 24 July 1989. Archived from the original on 10 March 2011. Retrieved 16 July 2012.
  33. ↑ "Forgotten: Ricky Bell". Pro Football Weekly. 8 January 2010. Archived from the original on 11 January 2010. Retrieved 26 January 2010.
  34. ↑ Jones T (12 October 2011). "Rob Buckman obituary". The Guardian. Archived from the original on 1 October 2013. Retrieved 16 July 2012.
  35. ↑ "'Dangal' actor Suhani Bhatnagar succumbs to dermatomyositis: Know about this rare condition". The Times of India. 18 February 2024.
  36. ↑ Ramos-E-Silva M, Pinto AP, Pirmez R, Cuzzi T, Carneiro SC (1 August 2016). "Dermatomyositis—Part 1: Definition, Epidemiology, Etiology and Pathogenesis, and Clinics". Skinmed. 14 (4): 273–279. PMID   27784516.

PD-icon.svg This article incorporates public domain material from NINDS Dermatomyositis Information Page. United States Department of Health and Human Services . Retrieved 12 December 2016.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.